JP2015524421A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524421A5 JP2015524421A5 JP2015523548A JP2015523548A JP2015524421A5 JP 2015524421 A5 JP2015524421 A5 JP 2015524421A5 JP 2015523548 A JP2015523548 A JP 2015523548A JP 2015523548 A JP2015523548 A JP 2015523548A JP 2015524421 A5 JP2015524421 A5 JP 2015524421A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- dengue
- use according
- serotype
- dengue virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000725619 Dengue virus Species 0.000 claims 14
- 208000025729 dengue disease Diseases 0.000 claims 12
- 208000001490 Dengue Diseases 0.000 claims 10
- 206010012310 Dengue fever Diseases 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 230000002238 attenuated effect Effects 0.000 claims 5
- 241000710831 Flavivirus Species 0.000 claims 2
- 241000710772 Yellow fever virus Species 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 229940051021 yellow-fever virus Drugs 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Claims (18)
- デング病に対するヒト対象の保護方法に使用するためのワクチン組成物であって、以下:
(i) 以下からなる群から選択されるデング抗原:
(a) 弱毒化生デングウイルス;
(b) 不活化デングウイルス;
(c) 弱毒化生、または不活化キメラデングウイルス;
(d) デングウイルス様粒子 (VLP); および
(e) (a)〜(d)の2つ以上の組合せ;
または
(ii) ヒト細胞において、デングVLPであるデング抗原を発現させることのできる核酸構築物またはウイルスベクター
を含む、ワクチン組成物。 - 該対象がデング免疫性である、請求項1記載の、使用するための組成物。
- 該ヒトが9〜16歳である、請求項1または2記載の、使用するための組成物。
- 該ヒトが9〜60歳である、請求項1または2記載の、使用するための組成物。
- 該ヒトが9〜45歳である、請求項1または2記載の、使用するための組成物。
- 該対象がデング流行地域に居住している、請求項1〜5のいずれか記載の、使用するための組成物。
- 該デング病が、血清型1、血清型3または血清型4のデングウイルスにより引き起こされる、請求項1〜6のいずれか記載の方法に使用するための組成物。
- 該方法が該組成物を3回以上投与することを含む、請求項1〜7のいずれか記載の、使用するための組成物。
- 該方法が、1回目、2回目および3回目に投与することを含み、2回目の投与を1回目の投与から約6ヶ月後に行い、3回目の投与を1回目の投与の約12ヶ月後に行う、請求項6〜8のいずれか記載の、使用するための組成物。
- 該組成物が血清型1のデング抗原、血清型2のデング抗原、血清型3のデング抗原および血清型4のデング抗原を含む、請求項1〜9のいずれか記載の、使用するための組成物。
- 該組成物が、弱毒化生デングウイルスまたは弱毒化生キメラデングウイルスを含む、請求項1〜10のいずれか記載の、使用するための組成物。
- 弱毒化生キメラデングウイルスを含む、請求項1〜11のいずれか記載の、使用するための組成物。
- 該キメラデングウイルスが、デングウイルス由来の1つ以上の蛋白質と、異なるフラビウイルス由来の1つ以上の蛋白質とを含む、請求項1〜12のいずれか記載の、使用するための組成物。
- 異なるフラビウイルスが、黄熱ウイルスである、請求項13記載の、使用するための組成物。
- 該キメラデングウイルスが、prM−E配列がデングウイルスのprM−E配列で置換された、黄熱ウイルスのゲノムを含む、請求項10〜14のいずれか記載の、使用するための組成物。
- 少なくとも1つの血清型デングウイルスが、約103〜約106 CCID50の量で存在する、請求項10〜15のいずれか記載の、使用するための組成物。
- 4つ全ての血清型のデングウイルスを含み、各血清型が約103〜約106 CCID50の量で存在する、請求項15記載の、使用するための組成物。
- 4つ全ての血清型のデングウイルスを含み、各血清型が約10 5 CCID 50 の量で存在する、請求項16記載の、使用するための組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12305907.3 | 2012-07-24 | ||
EP12305907 | 2012-07-24 | ||
EP12305912 | 2012-07-25 | ||
EP12305912.3 | 2012-07-25 | ||
PCT/EP2013/065667 WO2014016360A1 (en) | 2012-07-24 | 2013-07-24 | Vaccine compositions |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019071529A Division JP6830118B2 (ja) | 2012-07-24 | 2019-04-03 | ワクチン組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015524421A JP2015524421A (ja) | 2015-08-24 |
JP2015524421A5 true JP2015524421A5 (ja) | 2016-09-08 |
Family
ID=48875047
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015523548A Ceased JP2015524421A (ja) | 2012-07-24 | 2013-07-24 | ワクチン組成物 |
JP2019071529A Active JP6830118B2 (ja) | 2012-07-24 | 2019-04-03 | ワクチン組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019071529A Active JP6830118B2 (ja) | 2012-07-24 | 2019-04-03 | ワクチン組成物 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20150196631A1 (ja) |
EP (2) | EP3932422A1 (ja) |
JP (2) | JP2015524421A (ja) |
KR (2) | KR20200067938A (ja) |
CN (1) | CN104812407B (ja) |
AU (1) | AU2013295014B2 (ja) |
CA (1) | CA2878682A1 (ja) |
MX (2) | MX381497B (ja) |
MY (2) | MY197723A (ja) |
PH (1) | PH12014502840B1 (ja) |
SG (2) | SG11201500412TA (ja) |
WO (1) | WO2014016360A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HK1212905A1 (zh) * | 2012-07-24 | 2016-06-24 | Sanofi Pasteur | 用於防止登革热病毒感染的疫苗组合物 |
PH12015502120B1 (en) | 2013-03-15 | 2024-02-16 | Takeda Vaccines Inc | Compositions and methods for dengue virus chimeric constructs in vaccines |
TWI852899B (zh) | 2014-09-02 | 2024-08-21 | 法商賽諾菲巴斯德公司 | 疫苗組合物 |
US10487120B2 (en) * | 2015-02-09 | 2019-11-26 | Academia Sinica | Epitope-substituted vaccine for use in improving safety and immunogenicity against dengue viruses |
US10857222B2 (en) | 2015-07-03 | 2020-12-08 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
EP3147294B1 (en) * | 2015-09-24 | 2020-04-29 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Distinguishing dengue virus infections from other flaviviral infections using a recombinant mutant envelope protein |
CA3005814C (en) * | 2015-11-27 | 2022-09-27 | The Chemo-Sero-Therapeutic Research Institute | Live virus having a bank of dengue virus attenuated strains, and a dengue vaccine containing same as antigens |
MX2018012459A (es) * | 2016-04-13 | 2019-06-06 | Takeda Vaccines Inc | Composiciones y metodos de vacunacion contra virus de dengue en niños y adultos jovenes. |
WO2018208741A1 (en) | 2017-05-08 | 2018-11-15 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Methods and compositions for the detection of flavivirus infections |
SG11202002933TA (en) * | 2017-10-05 | 2020-04-29 | Sanofi Pasteur | Compositions for booster vaccination against dengu |
WO2019113285A2 (en) | 2017-12-06 | 2019-06-13 | Emory University | Zika vaccines and methods of use |
EP3549603A1 (en) | 2018-04-06 | 2019-10-09 | Sanofi Pasteur | Live-attenuated yellow fever virus strain adapted to grow on vero cells and vaccine composition comprising the same |
US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
CN112912106A (zh) | 2018-09-05 | 2021-06-04 | 武田疫苗股份有限公司 | 登革热疫苗单位剂量及其施用 |
CN112079934B (zh) * | 2019-12-17 | 2021-01-29 | 合源生物科技(天津)有限公司 | 一种靶向cd19的嵌合抗原受体及其用途 |
CN116334070A (zh) * | 2023-02-15 | 2023-06-27 | 天津大学 | 融合蛋白的应用和细胞融合的方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5422A (en) | 1848-02-01 | Spark-arrester | ||
US109A (en) | 1836-12-15 | Erawijtg | ||
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
FR2649013B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable |
FR2649012B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Emulsions multiphasiques injectables |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6254873B1 (en) | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
AU6093296A (en) | 1995-06-07 | 1996-12-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
PT1625852E (pt) | 1997-02-28 | 2010-08-27 | Acambis Inc | Vacinas quiméricas de flavivírus |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
ES2298316T3 (es) | 1997-09-05 | 2008-05-16 | Glaxosmithkline Biologicals S.A. | Emulsiones de aceite en agua que contienen saponinas. |
EP1165128A2 (en) | 1999-03-26 | 2002-01-02 | Walter Reed Army Institute of Research | Attenuated dengue-2 virus vaccine |
US6528065B1 (en) | 1999-03-26 | 2003-03-04 | The United States Of America As Represented By The Secretary Of The Army | Attenuated dengue-3 virus vaccine |
WO2000057908A2 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research, Department Of The Army | Attenuated dengue-1 virus vaccine |
WO2000057910A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-4 virus vaccine |
EP1263965B1 (en) | 2000-02-16 | 2011-09-28 | The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services | Avirulent, immunogenic flavivirus chimeras |
PT1159968E (pt) | 2000-05-30 | 2008-11-20 | Univ Mahidol | Estirpes atenuadas de vírus do dengue e a sua utilização numa composição de vacina |
AT410634B (de) | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
CA3060687C (en) | 2001-05-22 | 2021-05-04 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
KR20040004642A (ko) | 2001-05-23 | 2004-01-13 | 덴드레온 샌 디에고 엘엘씨 | 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도 |
JP2005501532A (ja) | 2001-06-01 | 2005-01-20 | アカンビス インコーポレーティッド | キメラフラビウイルスベクター |
KR101194818B1 (ko) * | 2002-01-15 | 2012-10-25 | 사노피 파스테르 바이오로직스, 엘엘씨 | 플라비바이러스 백신 |
WO2003101397A2 (en) | 2002-05-31 | 2003-12-11 | Acambis, Inc. | Tetravalent dengue vaccines |
CA2611934C (en) * | 2005-06-17 | 2015-11-03 | Sanofi Pasteur | Dengue serotype 1 attenuated strain |
CA2611954C (en) | 2005-06-17 | 2014-01-28 | Sanofi Pasteur | Dengue serotype 2 attenuated strain |
AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
WO2007021672A2 (en) | 2005-08-10 | 2007-02-22 | Acambis Inc. | Vaccination against dengue virus infection |
BRPI0618850A2 (pt) * | 2005-11-21 | 2011-09-13 | Sanofi Pasteur Ltd | formulações de estabilização para vìrus recombinantes |
FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
US7968102B2 (en) * | 2006-01-13 | 2011-06-28 | Sanofi Pasteur S.A. | Dengue chimeric viruses |
FR2903605A1 (fr) | 2006-07-12 | 2008-01-18 | Sanofi Pasteur Sa | Methode d'immunisation contre les quatres serotypes de la dengue |
FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
FR2909286B1 (fr) | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
GB201007531D0 (en) | 2010-05-05 | 2010-06-23 | Imp Innovations Ltd | Composition |
-
2013
- 2013-07-24 US US14/416,496 patent/US20150196631A1/en not_active Abandoned
- 2013-07-24 AU AU2013295014A patent/AU2013295014B2/en active Active
- 2013-07-24 SG SG11201500412TA patent/SG11201500412TA/en unknown
- 2013-07-24 JP JP2015523548A patent/JP2015524421A/ja not_active Ceased
- 2013-07-24 CA CA2878682A patent/CA2878682A1/en active Pending
- 2013-07-24 WO PCT/EP2013/065667 patent/WO2014016360A1/en active Application Filing
- 2013-07-24 MY MYPI2018700631A patent/MY197723A/en unknown
- 2013-07-24 CN CN201380049627.XA patent/CN104812407B/zh active Active
- 2013-07-24 EP EP21173406.6A patent/EP3932422A1/en active Pending
- 2013-07-24 EP EP13741748.1A patent/EP2877208B1/en active Active
- 2013-07-24 MY MYPI2014003501A patent/MY168959A/en unknown
- 2013-07-24 MX MX2015000442A patent/MX381497B/es unknown
- 2013-07-24 SG SG10201912291YA patent/SG10201912291YA/en unknown
- 2013-07-24 KR KR1020207016038A patent/KR20200067938A/ko not_active Ceased
- 2013-07-24 KR KR20157003821A patent/KR20150036592A/ko not_active Ceased
-
2014
- 2014-12-19 PH PH12014502840A patent/PH12014502840B1/en unknown
-
2015
- 2015-01-09 MX MX2021004211A patent/MX2021004211A/es unknown
-
2018
- 2018-09-06 US US16/123,319 patent/US20190201517A1/en not_active Abandoned
-
2019
- 2019-04-03 JP JP2019071529A patent/JP6830118B2/ja active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015524421A5 (ja) | ||
Trovato et al. | Viral emerging diseases: challenges in developing vaccination strategies | |
Yong et al. | Recent advances in the vaccine development against Middle East respiratory syndrome-coronavirus | |
JP2017526689A5 (ja) | ||
Belete | A review on Promising vaccine development progress for COVID-19 disease | |
Khetarpal et al. | Dengue fever: causes, complications, and vaccine strategies | |
JP2019151636A5 (ja) | ||
JP2015524422A5 (ja) | ||
Li et al. | Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates | |
DeFilippis | Chikungunya virus vaccines: platforms, progress, and challenges | |
Golden et al. | The strategic use of novel smallpox vaccines in the post-eradication world | |
Huang et al. | Vaccine development for mosquito-borne viral diseases | |
Moreno et al. | Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge | |
CO6541529A2 (es) | Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos | |
Torres-Ruesta et al. | Insights into antibody-mediated alphavirus immunity and vaccine development landscape | |
Plummer et al. | Mouse models for dengue vaccines and antivirals | |
Norrby | Outlook for a dengue vaccine | |
Zhang et al. | Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71 | |
Kim et al. | Cross-protective immune responses elicited by a Korean variant of infectious bronchitis virus | |
Medina et al. | Virulence and immune evasion strategies of FMDV: implications for vaccine design | |
AR067439A1 (es) | Virus quimericos antigenicos de virus de encefalitis de st. louis/virus dengue tipo 4 | |
Patel et al. | Understanding COVID-19 vaccines and their development | |
WO2017116177A3 (ko) | 약독화된 돼지열병 바이러스 생마커백신주 및 이를 이용한 경구투여용 백신 조성물 | |
JP2020536107A5 (ja) | ||
Murala et al. | Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2 |